Moderna Expands mRNA Capability Through $85m OriCiro Acquisition

Moderna has made its first-ever acquisition with the $85m purchase of OriCiro Genomics, a Japanese bioventure with DNA synthesis and amplification technology. The deal is expected to contribute to Moderna’s capabilities in both manufacturing and R&D.

DNA amplification and synthesis technology of OriCiro has already attracted more than $10m financing in Japan
OriCiro's DNA amplification and synthesis platform had already attracted more than $10m in financing • Source: Shutterstock

High-profile mRNA specialist Moderna, Inc. has put some of its financial windfall from the COVID-19 pandemic to use by entering into a definitive agreement to acquire OriCiro Genomics, a Japanese bioventure based in Tokyo with cell-free DNA synthesis and amplification technologies, for $85m.

The deal marks the first acquisition by the US-based firm, which sprung to global prominence during the pandemic for its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.